Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | GFER | P55789 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744416 | 0.88 | PDE5A (0.62) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29352550 | 0.87 | PDE5A (1.00) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10252544 | 0.87 | PDE5A (0.77) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL187837 | 0.87 | PDE5A (1.00) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5004337 | 0.85 | PDE5A (0.82) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24777457 | 0.84 | PDE5A (0.72) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4849350 | 0.84 | PDE5A (1.00) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14290111 | 0.84 | PDE5A (0.72) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13199036 | 0.82 | PDE5A (0.69) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7492367 | 0.82 | PDE5A (1.00) | PDE5ACYP2D6CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1842332-A | Compounds, compositions and methods | HIF BIO INC (US) | 2006-10-04 | — | — | CN | claimed |
| EP-1646382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO INC. (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | claimed |
| WO-2005030121-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-7226941-B2 | Compound for treating angiogenesis | HIF BIO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1842332-A | Compounds, compositions and methods | HIF BIO INC (US) | 2006-10-04 | — | — | CN | disclosed |
| EP-1686127-A1 | New heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases | Bayer HealthCare AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| EP-1646382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO INC. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-6462068-B1 | CARDIOVASCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| US-6414009-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6410740-B1 | CYCLIZATION OF THE CORRESPONDING AMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-25 | — | — | US | disclosed |
| US-6387942-B2 | PYRAZOLYL COMPOUND; ANTICOAGULANTS, ANTIPROLIFERATIVE AGENT | YUNG SHIN PHARMACEUTICAL IND. CO. LTD (TW) | 2002-05-14 | — | — | US | disclosed |
| US-6387940-B1 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2002-01-10 | — | — | US | disclosed |
| EP-1166785-A1 | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation | Yung Shin Pharmeutical Ind. Co., Ltd. (TW) | 2002-01-02 | — | — | EP | disclosed |
| US-6166027-A | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | PDE5A 255/4885CYP2D6 3055/4885CYP1A2 2320/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | PDE5A 250/4885CYP2D6 3045/4885CYP1A2 2317/4885 |
| US-20050187276-A1 | Compounds, compositions and methods | HIF1A, HIF1AN, EGLN3 | PDE5A 1987/4885CYP2D6 3521/4885CYP1A2 2118/4885 |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | F2R, HPN, F2RL1 | PDE5A 3372/4885CYP2D6 2836/4885CYP1A2 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.